Vinorelbina nel trattamento del carcinoma mammario: Attualita e prospettive future

Translated title of the contribution: Vinorelbine in the treatment of breast cancer: Current status and future perspectives

F. Conti, P. Vici

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To evaluate efficacy and tolerability of vinorelbine in breast cancer. Design: A review of most significant and recent clinical trials was performed. Results: Vinorelbine as single agent showed 44% and 17-36% of response as 1(st) and 2(nd) line treatment, respectively. When combined with other agents, these figures were the following: cisplatin, 73%-75% and 43- 64%; mitomycin C, up to 92% and 33%-69%; 5-fluorouracil, 33%-64% and 22%- 55%; ifosfamide, 57% and 28%; taxol, 78% and 54%; taxotere, up to 80%; mitoxantrone, 44%-68% and 31%-40%; doxorubicin, 57%-82% and 30%-33%; epirubicin, 22%-78% and 33%. Vinorelbine-epirubicin combination appears to be very active in neoadjuvant setting, with up to 92% response rates. Conclusions: Vinorelbine activity is significant and similar to that of the most active antineoplastic drugs in breast cancer. The most promising combinations appear to be with anthracyclines, taxanes or mitomycin C, even in heavily pretreated patients. Some aspects, such as optimal dose and scheduling and the inclusion in adjuvant programs or in new combination regimens remain to be defined.

Original languageItalian
Pages (from-to)61-74
Number of pages14
JournalClinica Terapeutica
Volume149
Issue number1
Publication statusPublished - Jan 1998

Fingerprint

Breast Neoplasms
Epirubicin
docetaxel
Mitomycin
Taxoids
Mitoxantrone
Ifosfamide
Anthracyclines
Therapeutics
Paclitaxel
Fluorouracil
Antineoplastic Agents
Doxorubicin
Cisplatin
Clinical Trials
vinorelbine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vinorelbina nel trattamento del carcinoma mammario : Attualita e prospettive future. / Conti, F.; Vici, P.

In: Clinica Terapeutica, Vol. 149, No. 1, 01.1998, p. 61-74.

Research output: Contribution to journalArticle

@article{30aed2c70e9d4bd38b1c64b5b85149fc,
title = "Vinorelbina nel trattamento del carcinoma mammario: Attualita e prospettive future",
abstract = "Purpose: To evaluate efficacy and tolerability of vinorelbine in breast cancer. Design: A review of most significant and recent clinical trials was performed. Results: Vinorelbine as single agent showed 44{\%} and 17-36{\%} of response as 1(st) and 2(nd) line treatment, respectively. When combined with other agents, these figures were the following: cisplatin, 73{\%}-75{\%} and 43- 64{\%}; mitomycin C, up to 92{\%} and 33{\%}-69{\%}; 5-fluorouracil, 33{\%}-64{\%} and 22{\%}- 55{\%}; ifosfamide, 57{\%} and 28{\%}; taxol, 78{\%} and 54{\%}; taxotere, up to 80{\%}; mitoxantrone, 44{\%}-68{\%} and 31{\%}-40{\%}; doxorubicin, 57{\%}-82{\%} and 30{\%}-33{\%}; epirubicin, 22{\%}-78{\%} and 33{\%}. Vinorelbine-epirubicin combination appears to be very active in neoadjuvant setting, with up to 92{\%} response rates. Conclusions: Vinorelbine activity is significant and similar to that of the most active antineoplastic drugs in breast cancer. The most promising combinations appear to be with anthracyclines, taxanes or mitomycin C, even in heavily pretreated patients. Some aspects, such as optimal dose and scheduling and the inclusion in adjuvant programs or in new combination regimens remain to be defined.",
keywords = "Breast cancer, Vinorelbine",
author = "F. Conti and P. Vici",
year = "1998",
month = "1",
language = "Italian",
volume = "149",
pages = "61--74",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "1",

}

TY - JOUR

T1 - Vinorelbina nel trattamento del carcinoma mammario

T2 - Attualita e prospettive future

AU - Conti, F.

AU - Vici, P.

PY - 1998/1

Y1 - 1998/1

N2 - Purpose: To evaluate efficacy and tolerability of vinorelbine in breast cancer. Design: A review of most significant and recent clinical trials was performed. Results: Vinorelbine as single agent showed 44% and 17-36% of response as 1(st) and 2(nd) line treatment, respectively. When combined with other agents, these figures were the following: cisplatin, 73%-75% and 43- 64%; mitomycin C, up to 92% and 33%-69%; 5-fluorouracil, 33%-64% and 22%- 55%; ifosfamide, 57% and 28%; taxol, 78% and 54%; taxotere, up to 80%; mitoxantrone, 44%-68% and 31%-40%; doxorubicin, 57%-82% and 30%-33%; epirubicin, 22%-78% and 33%. Vinorelbine-epirubicin combination appears to be very active in neoadjuvant setting, with up to 92% response rates. Conclusions: Vinorelbine activity is significant and similar to that of the most active antineoplastic drugs in breast cancer. The most promising combinations appear to be with anthracyclines, taxanes or mitomycin C, even in heavily pretreated patients. Some aspects, such as optimal dose and scheduling and the inclusion in adjuvant programs or in new combination regimens remain to be defined.

AB - Purpose: To evaluate efficacy and tolerability of vinorelbine in breast cancer. Design: A review of most significant and recent clinical trials was performed. Results: Vinorelbine as single agent showed 44% and 17-36% of response as 1(st) and 2(nd) line treatment, respectively. When combined with other agents, these figures were the following: cisplatin, 73%-75% and 43- 64%; mitomycin C, up to 92% and 33%-69%; 5-fluorouracil, 33%-64% and 22%- 55%; ifosfamide, 57% and 28%; taxol, 78% and 54%; taxotere, up to 80%; mitoxantrone, 44%-68% and 31%-40%; doxorubicin, 57%-82% and 30%-33%; epirubicin, 22%-78% and 33%. Vinorelbine-epirubicin combination appears to be very active in neoadjuvant setting, with up to 92% response rates. Conclusions: Vinorelbine activity is significant and similar to that of the most active antineoplastic drugs in breast cancer. The most promising combinations appear to be with anthracyclines, taxanes or mitomycin C, even in heavily pretreated patients. Some aspects, such as optimal dose and scheduling and the inclusion in adjuvant programs or in new combination regimens remain to be defined.

KW - Breast cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0031807221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031807221&partnerID=8YFLogxK

M3 - Articolo

C2 - 9621491

AN - SCOPUS:0031807221

VL - 149

SP - 61

EP - 74

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 1

ER -